News | October 22, 2007

SPIRIT III Shows Less MACE for Xience than Taxus

October 23, 2007 – After 12 months of the SPIRIT III trial, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent, researchers reported at TCT 2007.
The rate of the primary endpoint, in-segment late loss was also reduced by 50 percent with the Xience V stent compared to Taxus. There were no significant differences in other secondary endpoints between the two stent types, including target vessel failure and stent thrombosis.
“Both the primary endpoint of the trial and the major secondary endpoint were met. Moeover, the reduction in major adverse cardiac events with the Xience V stent compared to the Taxus stent is an important finding that signifies improved long-term outcomes for patients with heart disease,” said Gregg W. Stone, M.D., chairman, Cardiovascular Research Foundation, professor of Medicine, Columbia University Medical Center.

For more information: www.crf.org


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now